Theranos Investor Conference Presentation Deck

Molecular Biology: NAA Zika Assay with Venous Serum is Consistent with Comparators Negative percent agreement Positive percent agreement Theranos/ Comparator 108 / 113 67/67 Percent Agreement 95.6% This technology has not been cleared or approved by the FDA and is not for sale in the United States. 100% Venous Serum (N=180) 78 from US (healthy and febrile subjects) 102 from Dominican Republic and Colombia (Zika symptomatic) 95% Confidence Interval (90.1%, 98.1%) (94.6%, 100.0%) theranos 56

View entire presentation